Our studies focus on the views that FBXW7 executes its tumor suppressor function by inhibition of EMT and the mTOR/p70S6K pathway, ensuring the efficiency of EGFR‐TKI treatment in NSCLC. This evidence concerns the gene RPS6KB1 and neoplasm.